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Abstract
Rationale: Ever-smokers without airflow obstruction scores greater
than or equal to 10 on the COPD Assessment Test (CAT) still have
frequent acute respiratory disease events (exacerbation-like),
impaired exercise capacity, and imaging abnormalities. Identification
of these subjects could provide new opportunities for targeted
interventions.
Objectives:We hypothesized that the four respiratory-related
items of the CAT might be useful for identifying such individuals,
with discriminative ability similar to CAT, which is an eight-item
questionnaire used to assess chronic obstructive pulmonary disease
impact, including nonrespiratory questions, with scores ranging
from 0 to 40.
Methods:We evaluated ever-smoker participants in the
Subpopulations and IntermediateOutcomes inCOPDStudywithout
airflow obstruction (FEV1/FVC>0.70; FVC above the lower limit of
normal). Using the area under the receiver operating characteristic
curve, we compared responses to both CAT and the respiratory
symptom–related CAT items (cough, phlegm, chest tightness,
and breathlessness) and their associations with longitudinal
exacerbations. We tested agreement between the two strategies
(k statistic), and we compared demographics, lung function, and
symptoms among subjects identified as having high symptoms by
each strategy.
Results: Among 880 ever-smokers with normal lung function
(mean age, 61 yr; 52%women) andusing aCATcutpoint greater than
or equal to 10, we classified 51.8% of individuals as having high
symptoms, 15.3% of whom experienced at least one exacerbation
during 1-year follow-up. After testing sensitivity and specificity of
different scores for the first four questions to predict any 1-year follow-
up exacerbation, we selected cutpoints of 0–6 as representing a low
burden of symptoms versus scores of 7 or higher as representing a high
burden of symptoms for all subsequent comparisons. The four
respiratory-related itemswithcutpoint greater thanor equal to7 selected
45.8% participants, 15.6% of whom experienced at least one
exacerbation during follow-up. The two strategies largely identified the
same individuals (agreement, 88.5%; k = 0.77; P, 0.001), and the
proportions of high-symptoms subjects who had severe dyspnea were
similar between CAT and the first four CAT questions (25.9% and
26.8%, respectively), as were the proportions reporting impaired quality
of life (66.9% and 70.5%, respectively) and short walking distance
(22.4% and 23.1%, respectively). There was no difference in area under
the receiver operating characteristic curve to predict 1-year follow-up
exacerbations (CAT score>10, 0.66; vs. four respiratory items from
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CAT>7 score, 0.65; P = 0.69). Subjects identified by eithermethod also
hadmore depression/anxiety symptoms, poor sleep quality, and greater
fatigue.
Conclusions: Four CAT items on respiratory symptoms identified
high-risk symptomatic ever-smokers with preserved spirometry as
well as the CAT did. These data suggest that simpler strategies
can be developed to identify these high-risk individuals in primary
care.
Keywords: obstructive lung disease; health status; questionnaires;
symptoms; quality of life
(Received in original form October 24, 2016; accepted in final form December 23, 2016 )
Supported by the National Health Institutes (NIH) under National Heart, Lung, and Blood Institute (NHLBI) grants K23 HL128936-01 and 3R01 HL122438-
02S1 (C.H.M.); by Merit Review Award I01 CX000911 from the Clinical Research and Development Service, Department of Veterans Affairs (J.L.C.); and by the
NIH under NHLBI grant R01HL122438-01 (M.K.H.) and NHLBI contracts HHSN268200900013C, HHSN268200900014C, HHSN268200900015C,
HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN2682009000019C, and HHSN268200900020C (Subpopulations and
Intermediate Outcomes in COPD Study [SPIROMICS]).
Author Contributions: All authors contributed to the conception, design, and analysis and drafting the manuscript, and all authors read and approved the final
version of the manuscript.
Correspondence and requests for reprints should be addressed to Carlos H. Martinez, M.D., M.P.H., Division of Pulmonary and Critical CareMedicine, University
of Michigan Health System, 3916 Taubman Center, Box 0360, 1500 East Medical Center Drive, Ann Arbor, MI 48109-5360. E-mail: carlosma@umich.edu
This article has an online supplement, which is accessible from this issue’s table of contents at www.atsjournals.org
Ann Am Thorac Soc Vol 14, No 5, pp 636–642, May 2017
Copyright © 2017 by the American Thoracic Society
DOI: 10.1513/AnnalsATS.201610-815OC
Internet address: www.atsjournals.org
The presence of airflow obstruction (defined
by FEV1/FVC ratio .0.7) is one of the
requirements for the diagnosis of chronic
obstructive pulmonary disease (COPD) (1).
However, there is growing recognition of the
presence of chronic bronchitis symptoms (2),
physical activity limitation, and acute
respiratory events (exacerbation-like
episodes) (3, 4) among ever-smokers without
airflow obstruction so defined (2, 3, 5).
The COPD Assessment Test (CAT) is
an eight-item questionnaire that includes
not only items focused on respiratory
symptoms (first four questions) but also
questions regarding activity limitation,
energy, and sleep (last four questions) (6).
Woodruff and colleagues recently
demonstrated that the well-validated CAT,
using the cutpoint of greater than or equal
to 10 points as recommended by Global
Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines, can reasonably
discriminate those individuals at risk of
exacerbations (3). The CAT is indicated for
use in patients meeting a spirometry-based
diagnosis of COPD, however, and is not
widely used in primary care, making it
necessary to develop and test novel strategies
for identification of these high-risk subjects.
In the present study, using data from
the same cohort, we tested if these subjects
with normal airflow but at high risk for
respiratory events could be more easily
identified using selected questions from
the CAT, a strategy with potential for
wider use in primary care. Specifically,
we hypothesized that among ever-smokers
without spirometrically defined airflow
obstruction, rating of respiratory symptoms
using the first four items (respiratory
symptom–related questions) from the CAT
would identify similar individuals and
would perform similarly to the CAT in the
ability to identify subjects with increased
risk for acute respiratory events.
Methods
Study Design and Participants
This is a cross-sectional and longitudinal
analysis of data from selected participants in
the National Institutes of Health–sponsored
Subpopulations and Intermediate Outcome
Measures in COPD Study (SPIROMICS)
(7), a prospective cohort study in which
researchers enrolled 2,981 participants with
the goals of identifying new COPD
subgroups and intermediate markers of
disease progression. SPIROMICS included
subjects aged 40–80 years in different strata,
including healthy never-smokers (<1
pack-year of tobacco smoking history) and
current or former smokers with a smoking
history of greater than 20 pack-years,
with or without obstructive lung disease.
For the present analyses, we included
ever-smoker (current or former)
SPIROMICS participants without airflow
obstruction (defined as post-bronchodilator
FEV1/FVC>0.70 and FVC greater than the
lower limit of normal). SPIROMICS was
approved by the institutional review boards
at all participating centers, including the
University of Michigan, where the present
analyses were performed. All participants
provided written informed consent.
Measurements
Participants provided information on
demographics, smoking status (former
or current) and history, and physician-
diagnosed diseases via standardized
questionnaires. All participants had baseline
spirometry measures, for which
SPIROMICS uses post-bronchodilator
spirometry values, with spirometry
performed following American Thoracic
Society recommendations on a
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pneumotachograph spirometer, with
predicted values based on Hankinson
reference equations (8).
At enrollment, we obtained
information on the following markers of
respiratory impairment: presence of chronic
bronchitis symptoms (defined as cough
and phlegm production for >3 consecutive
mo per yr for 2 or more yr, based on the
response to the questions on cough and
phlegm production from the American
Thoracic Society Respiratory Epidemiology
Questionnaire) (9), dyspnea severity using
the modified Medical Research Council
dyspnea scale (mMRC) score (10) (further
categorized as 0–1 and 2–4 as per GOLD
recommendations [1]), distance walked in a
6-minute walk test (used in analyses as a
continuous variable or further categorized
as ,250 m and >250 m) (5), respiratory
events or exacerbations in the 1 year prior
to enrollment, and health-related quality-
of-life metrics using the St. George’s
Respiratory Questionnaire (continuous
variable and with scores categorized as <25
and .25) (11).
We also collected information on
the presence of anxiety and depression
symptoms using the Hospital Anxiety and
Depression Scale (further categorized as
score >8 representing high symptoms) (12),
sleep quality measured by the Pittsburgh
Sleep Quality Index (with score .5
indicating poor sleep quality) (13),
fatigue using the Functional Assessment
of Chronic Illness Therapy–Fatigue scale
(with values <33 considered as significant
fatigue) (14), and exercise tolerance
using the Veterans Specific Activity
Questionnaire (with predicted ability
less than 5 metabolic equivalents being
considered as low exercise tolerance) (15).
Participants in the present analysis were
followed every 3 months for 1 year
to identify acute respiratory disease events
(hereafter described as exacerbations),
defined as use of antibiotic agents, systemic
glucocorticoids, or both or as need for
unplanned office, emergency department,
or admissions because of respiratory
symptoms (exacerbations requiring health
care use) (7).
To identify subjects with a high burden
of symptoms, we used the CAT, a validated
health status questionnaire with recall
time of 6 weeks, which includes eight
questions, each rated on a 5-point scale (6).
CAT is a copyrighted instrument used in
SPIROMICS under license agreement with
its proprietor. We selected CAT as the
definition of symptom burden because it is
part of the GOLD recommendations (1).
For the present analyses, we compared
two different strategies to identify high-
symptoms subjects. In the first, we used the
CAT (scale 0–40, with 0–9 classified as low
symptom burden and >10 as high
symptom burden, as recommended by
GOLD strategy document) (1). In the
alternate method, we used only the first
four items (respiratory symptom–related
questions) of the CAT, which resulted in
a score of 0–20. We identified a cutpoint
for the four questions testing associations
between all possible scores and based on
its associations with any 1-year follow-up
exacerbation. We took this approach
because there are no normative values
derived from four items, but for the
complete instrument (16), CAT
questionnaires were applied at enrollment
by trained research coordinators who were
unware of the planned analyses.
Statistical Analysis
Descriptive statistics were based on
proportions and means (with SD),
according to the variable of interest. The
agreement between CAT and the respiratory
question subset of CAT to identify similar
groups of participants as having a high
burden of symptoms was calculated using
the k statistic. To compare both CAT and
the first four questions with the predefined
cutpoints, we tested their association with
other measures of health impact and
impairment, which were selected as the
reference standard.
For a cross-sectional comparison,
we tested associations with health-related
quality of life, which we measured by
St. George’s Respiratory Questionnaire
total score, walking distance, and baseline
exacerbations. During longitudinal follow-
up, we used as a reference the associations
with exacerbations/acute respiratory events
during 1-year follow-up. The association was
measured by the area under the receiver
operating characteristic curve (AUC), and
the AUCs were compared. The analysis
assumed an AUC of 0.68 for the association
between CAT and any exacerbation during
the 1-year follow-up, and, using a probability
of type I error of 5% and a power of 80%
to detect a 5% difference between CAT and
the respiratory item subset, inclusion of at
least 707 participants would allow detection
of a difference of 0.05 between AUCs.
We also calculated the sensitivity and
specificity of CAT and the first four items
to predict any exacerbation during follow-
up. Finally, in prespecified analyses, we
tested if the strategies had similar
performance across different demographic
groups defined by age, sex, and race. All
analyses were conducted using STATA
version 12 software (StataCorp, College
Station, TX), and a P value less than 0.05
was considered significant.
Results
We included 880 ever-smokers with preserved
lung function among the 2002 SPIROMICS
participants. Figure E1 in the online
supplement shows the flow of participants
through the present study. Overall, half of the
ever-smokers with preserved lung function
were women, one-fourth were of African
American race, and half were current
smokers. Participants described the presence
of chronic bronchitis symptoms (18.6%),
dyspnea with mMRC score greater than
or equal to 2 (15.5%), and short walking
distance (15.9%). Among different comorbid
conditions reported were obesity (defined
as body mass index [BMI] >30 kg/m2) in
40% and asthma in 18% (Table E1).
After testing sensitivity and
specificity of different scores of the first four
questions to predict any 1-year follow-up
exacerbation, we selected scores of 0–6 as
a low burden of symptoms and 7 or higher
as a high burden of symptoms, and these
were used as cutpoints for all subsequent
comparisons. The sensitivity and specificity
for all possible cutpoints are presented
in Table E2. Using the CAT with a cutpoint
of greater than or equal to 10 points,
we identified 456 participants with
high symptom burden. Using the four
respiratory items of CAT only, score greater
than or equal to 7 points identified 403
subjects with high symptom burden. The
agreement was 88.5% (k = 0.77; P, 0.001).
Both groups had similar demographic
and clinical characteristics (Table 1).
At enrollment, the proportion of high-
symptoms subjects who had severe dyspnea
was similar between the CAT and the first
four CAT questions (25.9% and 26.8%,
respectively), as were the frequencies with
which subjects reported impaired quality of
life (66.9% and 70.5%, respectively) and had
short walking distance (22.4% and 23.1%,
respectively) (Table 2).
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Among participants identified with
high symptom burden by CAT, 15.1% had
at least one exacerbation during the first
year of follow-up. For those identified by
the respiratory symptoms questions of
CAT, the frequency was 14.1%. The
association between high symptom
burden by CAT (score >10 points) and
any exacerbation during follow-up had an
AUC of 0.66, whereas for the first four
CAT questions (score >7 points), the
AUC was 0.65 (P = 0.69 for comparison of
the two curves).
When exacerbations were classified by
use of antibiotics/steroids, the AUCs were
0.65 and 0.65, respectively (P = 0.76 for
comparison of both curves). For
exacerbations requiring health care use,
the AUCs were 0.65 and 0.64, respectively
(P = 0.58 for comparison of the two curves)
(Table 2). A cutpoint of 10 using CAT was
associated with a sensitivity of 0.80 and
a specificity of 0.52 for any exacerbation,
whereas the cutpoint of 7 for the selected
respiratory items of CAT resulted in a
sensitivity of 0.73 and a specificity of 0.58.
Similar associations were found for the
presence of different markers of respiratory-
related impairment at enrollment. The
association between high symptom burden
by CAT (score >10 points) and impaired
quality of life at enrollment showed an
AUC of 0.81, whereas for the first four CAT
questions (score >7 points), the AUC was
0.81 (P = 0.87 for comparison of both
curves). The association of CAT score
greater than or equal to 10 points and short
walking distance showed an AUC of 0.62,
whereas for the selected CAT items
(score >7 points), the AUC was 0.62
(P = 0.86 for comparison of both curves)
(Table 2).
Because CAT includes questions on
health status that are not necessarily
respiratory related, we also tested whether
subjects identified with high symptoms
(using any strategy) could also have other
markers of health impairment not related
exclusively to respiratory function. We
found that, compared with those in the low-
symptom category, subjects reported with
higher frequency a high burden of anxiety
and depression symptoms, more frequently
had low ability to exercise, and reported fatigue
and had poor-quality sleep with higher
frequency. These additional health concerns
had a similar frequency in the high-symptom
group, regardless of the strategy used to
identify them (CAT or respiratory questions of
CAT) (Table 3).
The two scoring strategies had an
agreement of 88.5% in subject classification
(400 subjects classified as low risk and 379 as
high risk by both strategies), leaving 101
discordant subjects. The majority of
discordant cases (n = 77) were subjects
classified as having low symptoms on the
basis of the first four questions of CAT but
as having high symptoms using the CAT
questionnaire. When we compared these 77
discordant subjects with the 400 judged as
having low symptoms on the basis of both
Table 1. Description of participants with preserved spirometry identified as high symptom burden by two different methods (n = 880)
Identified by CAT >10
points (n = 456)
Identified by Respiratory
Questions of CAT >7
points (n = 403)
P Value
Demographics
Age, yr, mean (SD) 59.4 (9.9) 59.1 (9.7) 0.74
Female sex, % 55.7 56.6 0.78
African American race, % 33.8 33.5 0.92
BMI, kg/m2, mean (SD) 29.8 (5.4) 29.8 (5.4) 1
Smoking history
Pack-years, mean (SD) 46.1 (26.4) 45.8 (26.6) 0.59
Currently smoking, % 57.2 58.3 0.74
Lung function
FEV1, L, mean (SD) 2.61 (0.70) 2.61 (0.70) 1
FEV1, % predicted, mean (SD) 92.0 (14.7) 92.2 (14.0) 0.38
Comorbid conditions, %
Obesity (BMI >30 kg/m2) 48.7 48.1 0.85
Asthma 27.6 29.3 0.58
Diabetes 19.3 19.1 0.94
Coronary artery disease 5.9 5.7 0.99
Markers of respiratory impact, %
Any respiratory event prior to enrollment 22.8 24.6 0.53
Chronic bronchitis symptoms* 30.9 35.0 0.20
mMRC dyspnea score >2† 25.9 26.8 0.76
Short distance during 6-min walk test‡ 22.4 23.1 0.81
Impaired quality of life measured by SGRQ total scorex 66.9 70.5 0.25
Any of the above 80.7 83.6 0.26
CAT score, mean (SD) 17.9 (6.4) 18.3 (6.7) 0.20
Definition of abbreviations: BMI = body mass index; CAT =COPD Assessment Test; mMRC=modified Medical Research Council dyspnea scale;
SGRQ= St. George’s Respiratory Questionnaire.
P value represents comparison of means or proportions among those identified by each strategy.
*Chronic bronchitis was defined as cough and phlegm production for at least 3 consecutive months per year for at least 2 years.
†Dyspnea was defined as mMRC score greater than or equal to 2.
‡Short walking distance was defined as distance walked in 6 minutes less than 250 m.
xImpaired quality of life was defined as an SGRQ total score greater than 25.
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strategies, they were more frequently
current smokers, had higher BMI, and
more frequently were of African American
race (Table E3). We found that compared
with results for male participants, when
applied to females, both strategies had
higher sensitivity but lower specificity.
Similarly, higher sensitivity and lower
specificity were found for both strategies in
African American participants (compared
with whites) and current smokers (versus
former smokers). CAT also had slightly
higher sensitivity than CAT respiratory
questions when applied to women and
African Americans (Table E4).
Finally, we tested if just asking
participants about the presence of dyspnea
(mMRC greater than or equal to 2), the
alternate way to identify subjects with high-
symptoms COPD according to the GOLD
recommendations (1), could identify
subjects similarly to the four respiratory-
related items of CAT. We found that the
AUC of 0.59 (95% confidence interval,
0.60–0.70) to predict 1-year exacerbations
was significantly lower when using mMRC
greater than or equal to 2 (P = 0.04 for
comparison of the two curves).
Discussion
We found that the four respiratory
symptom items of the CAT, using a
threshold of 7 points or higher, identified a
group of former or current smokers with
preserved spirometry similar to those
selected using the CAT with a threshold
10 points or higher. Both groups had similar
symptom burden, and both strategies
were comparable in their prediction of
respiratory events (exacerbations) during
longitudinal follow-up. These findings
confirm previous reports about the high
frequency of symptoms of respiratory
impairment among ever-smokers who do
not satisfy the current spirometric definition
of COPD (2, 3, 5), and they also provide a
proof of the concept that simpler strategies
can be developed and tested to identify
these subjects in primary care. For example,
in the present study, the decision about the
cutpoint selection when using the selected
items of CAT was based on a trade-off
between sensitivity and specificity of
all possible scores in the participant
population, but it is unclear if this can
be extrapolated to other studies without
further validation.
The current definition of COPD relies
on the presence of spirometric measures of
airflow obstruction (1). However, it is clear
that not all current and former smokers
Table 2. Use of two strategies used to identify subjects with high symptom burden to predict quality of life, physical activity, and
exacerbations (n = 880)
CAT >10 points
AUC (95% CI)
Respiratory Questions of CAT >7
points AUC (95% CI)
P Value
Cross-sectional associations
Any respiratory event prior to enrollment 0.66 (0.62–0.70) 0.67 (0.63–0.71) 0.77
Dyspnea* 0.70 (0.67–0.74) 0.69 (0.66–0.73) 0.59
Short distance in 6-min walk test† 0.62 (0.58–0.66) 0.62 (0.57–0.66) 0.86
Impaired quality of life measured by SGRQ total
score‡
0.81 (0.79–0.83) 0.81 (0.78–0.83) 0.87
Longitudinal exacerbations (during 1-yr follow-up)
Any 0.66 (0.61–0.70) 0.65 (0.60–0.70) 0.69
Any requiring steroids or antibiotics 0.65 (0.60–0.70) 0.65 (0.60–0.71) 0.76
Any requiring health-care use 0.65 (0.60–0.69) 0.64 (0.58–0.69) 0.58
Definition of abbreviations: AUC = area under the receiver operating characteristic curve; CAT = COPD Assessment Test; CI = confidence interval;
SGRQ= St. George’s Respiratory Questionnaire.
P value is for the comparison of AUCs.
*Dyspnea was defined as modified Medical Research Council dyspnea scale score greater than or equal to 2.
†Short walking distance was defined as distance walked in 6 minutes less than 250 m.
‡Impaired quality of life was defined as SGRQ total score higher than 25.
Table 3. Additional markers of health impairment among participants with preserved
lung function identified as high symptom burden by two different methods (n = 880)
Identified by
CAT >10
points (n = 456)
Identified by Respiratory
Questions of
CAT >7 points (n = 403)
P Value
High burden of anxiety
symptoms*
42.8 44.9 0.53
High burden of depression
symptoms†
24.3 25.8 0.61
Poor sleep quality‡ 63.2 67.5 0.18
Fatiguex 41.9 41.9 1.0
Low exercise tolerancek 59.9 60.8 0.78
Definition of abbreviation: CAT = COPD Assessment Test.
Data shown as percentage. P value represents comparison of means or proportions among those
identified by each strategy.
*High burden of anxiety symptoms was defined as Hospital Anxiety and Depression Scale anxiety
score greater than or equal to 8.
†High burden of depression symptoms was defined as Hospital Anxiety and Depression Scale
depression score greater than or equal to 8.
‡Poor sleep quality was defined as Pittsburgh Sleep Quality Inventory score greater than 5.
xFatigue defined was defined as Functional Assessment of Chronic Illness Therapy–Fatigue scale
score greater than or equal to 33.
kLow exercise was defined as Veterans Specific Activity Questionnaire score less than 5 metabolic units.
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without airflow obstruction are free of a
disease. Growing evidence from several
cohorts suggests that individuals with
smoking history without airflow
obstruction may still have significant
respiratory symptoms and are at risk for
poor outcomes, in some cases similar to
those of individuals with established airflow
obstruction. Efforts to prevent further
clinical deterioration and poor outcomes
among smokers with preserved spirometry
should start by testing different tools
to identify this at-risk population.
SPIROMICS investigators have
previously demonstrated that the well-
validated CAT, using the cutpoint of
10 points or o higher as recommended
by GOLD guidelines, can reasonably
discriminate those individuals at risk of
exacerbations (3), findings that are aligned
with what is known about subjects with
established COPD. We extend these
findings by showing that using the
respiratory questions of CAT with a
cutpoint score of 7 points or higher has
similar associations with clinical descriptors
of respiratory impairment (short walking
distance, more severe dyspnea, impaired
quality of life) and longitudinal
exacerbations, as shown by similar
AUCs using any of those strategies.
The differences between subjects
scoring less than 7 points versus those
scoring 7 points or higher on the four
respiratory questions of CAT are similar in
magnitude and direction to those previously
reported by Woodruff and coworkers (3), as
shown in Table E5. Our findings provide
evidence that using only respiratory
symptom–related questions could facilitate
identification of these subjects by busy
primary care providers, expanding the
available tools for identification of ever-
smokers without airflow obstruction but
at risk of poor outcomes. In the present
study, CAT and selected CAT respiratory
questions not only had a similar overall
classification of high-symptoms subjects, as
measured by the AUC, but also had very
similar sensitivity and specificity. CAT was
associated with a sensitivity of 0.80 and a
specificity of 0.52 for any 1-year follow-up
exacerbation, whereas the respiratory
questions of the CAT had a sensitivity
of 0.73 and a specificity of 0.58.
CAT and the selected CAT respiratory
questions exhibited significant agreement in
determining subjects with high burden of
symptoms, but they also were discordant
in some subjects. Some of the discordant
individuals belong to groups for whom there
is previous evidence of disparities in
respiratory care; hence, we examined
them in more detail. Women have been
recognized as being diagnosed with
obstructive lung disease with lower
frequency than men (17), even in the
presence of similar symptoms. We found
that both strategies to identify high
symptoms in smokers with normal lung
function have similar AUC, whereas the
specificity of the respiratory items of CAT
is slightly better than that of CAT. The
strategies to identify subjects with high
symptom burden also perform well among
former smokers, and actually using the first
four questions of CAT had high sensitivity
and specificity in this group.
An interesting finding which deserves
further exploration is that both CAT and the
respiratory questions of CAT were
associated with a low specificity among
participants of African American race,
although the specificity was slightly higher
with the respiratory questions. This finding
is relevant because African Americans are a
population group for whom there is a need
to develop better models to understand the
impact of tobacco-related lung disease
(18, 19). Still, among African Americans,
the sensitivity of both strategies was as high
as or higher than in other groups. Overall, it
is worth recognizing that the classification
statistics (sensitivity and specificity) and
discriminative ability (AUCs around 0.65)
of both strategies need to be improved in
the future. Still, they represent an advance
because they are calling attention to a
group of subjects previously considered
“healthy smokers” owing to the absence of
airflow obstruction, at least as defined by
FEV1/FVC less than 70%. The values
are also similar to what was previously
reported using the CAT with similar
subjects (3).
Limitations
Our study is subject to several limitations.
The most important is that it is not
based on a representative sample of the
population; it is based on research
volunteers recruited at tertiary care medical
centers. However, the sample was inclusive
and had a large proportion of women
and minority participants, which makes
the results easier to translate into clinical
practice. Our analyses could be interpreted
as a comparison of diagnostic and prognostic
tools, and we agree with that idea and present
a complete description using the Standards
for Reporting Diagnostic Accuracy Studies
recommendations in Table E6 (20).
Unfortunately, the two diagnostic
strategies lack a clearly defined gold
standard with which to be compared. To
minimize this potential limitation, we
used for comparison an outcome standard
(exacerbation during follow-up) and
additional cross-sectional reference
standards using patient characteristics not
included in the CAT (walking distance,
quality-of-life metrics).
In the present study, we used the
responses to selected CAT items to
understand which areas of the participants’
health were more affected and if they were
strongly associated with exacerbations.
Nonetheless, we should note that the
CAT was validated as an eight-item
questionnaire and that using questions
independently of each other could change
the integrity and measurement properties of
the questionnaire; an assessment of the
measurement properties that result from
reducing the number of items in this
questionnaire is beyond the scope of this
paper. Equally important, CAT was designed
to be applied to subjects with a diagnosis of
COPD, whereas our study population
consisted of participants without airflow
obstruction. Strengths of the study
include the detailed characterization of
participants, careful follow-up to identify
the outcome standard selected to
compare the two strategies of using the
CAT, and the robustness of results in
different disease spectra and subgroups
of subjects.
Conclusions
Using the four respiratory questions of the
CAT with a cutpoint score of 7 or higher
identifies a group of smokers with preserved
spirometry similar to that identified with the
CAT cutpoint score of 10 or higher, who
have a greater burden of dyspnea, chronic
bronchitis, activity limitation, and impaired
quality of life, as well as increased risk for future
exacerbations. These findings provide further
evidence of a relationship between respiratory
symptoms and risk for respiratory events, and
they provide support for future development of
simpler strategies to identify these high-risk
subjects in primary care. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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Supplementary Table 1. Description of SPIROMICS participants with preserved lung function 
included in the analysis (n=880) 
 
Demographics 
Age (mean, s.d.) 60.7 (9.8) 
Female gender (%) 51.6 
African American (%) 25.6 
BMI (mean, s.d.) 28.8 (5.2) 
Smoking history 
Pack-years smoked (mean, s.d.) 44.0 (24.1) 
Currently smoking (%) 49.7 
Lung function 
FEV1 in liters (mean, s.d.) 2.73 (0.72) 
FEV1 % predicted (mean, s.d.) 95.0 (14.2) 
Markers of respiratory impact 
Any respiratory event prior to enrollment  14.9 
Chronic bronchitis symptoms  18.6 
Dyspnea 15.5 
Low walking distance  15.9 
High SGRQ 38.2 
Comorbid Conditions (%) 
Obesity (BMI ≥30 kg/m2) 40.0 
Asthma 18.3 
Diabetes  14.1 
Coronary artery disease 5.1 
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Supplementary Table 2. Sensitivity and specificity for any one-year follow-up exacerbation for 
each possible score using only the first four items of CAT 
Score Area under the curve ROC Sensitivity Specificity 
1 0.503 0.95 0.05 
2 0.537 0.95 0.12 
3 0.563 0.85 0.22 
4 0.602 0.88 0.32 
5 0.612 0.81 0.41 
6 0.623 0.74 0.50 
7 0.654 0.73 0.57 
8 0.674 0.69 0.65 
9 0.642 0.55 0.72 
10 0.632 0.48 0.77 
11 0.611 0.39 0.82 
12 0.601 0.32 0.87 
13 0.599 0.29 0.90 
14 0.577 0.22 0.93 
15 0.545 0.14 0.95 
16 0.527 0.08 0.97 
17 0.513 0.04 0.98 
18 0.500 0.01 0.98 
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Supplementary Table 3. Description of participants classified as discordant by two methods 
used to identify subjects with high symptom burden preserved lung function (n=880) 
 Low symptoms 
by both methods 
(n=400) 
Low symptoms 
by respiratory 
questions of 
CAT only 
(n=77) 
P=value 
Demographics    
Age (mean, s.d.) 62.3 (9.5) 60.6 (10.6) 0.17 
Female gender (%) 47.0 49.3 0.70 
African American (%) 16.2 32.5 0.005 
BMI (mean, s.d.) 27.8 (4.8) 29.1 (5.2) 0.02 
Smoking history    
Pack-years smoked (mean, s.d.) 42.0 (21.5) 45.0 (22.5) 0.25 
Currently smoking (%) 40.0 54.6 0.02 
Lung function    
FEV1 in liters (mean, s.d.) 2.87 (0.72) 2.64 (0.66) 0.01 
FEV1 % predicted (mean, s.d.) 98.2 (13.0) 92.9 (17.1) 0.002 
Markers of respiratory impact    
Any respiratory event prior to 
enrollment (%) 
6.5 7.8 0.67 
Chronic bronchitis symptoms 
(%) 
4.0 9.1 0.06 
mMRC score ≥2 4.0 15.6 <0.001 
Six minute walking distance 
<250 m  
9.0 14.3 0.15 
Comorbid Conditions (%)    
Obesity (BMI ≥30 kg/m2) 30.8 45.5 0.01 
Asthma 8.0 14.3 0.07 
Diabetes  8.3 16.9 0.04 
Coronary artery disease 4.5 5.2 0.72 
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Supplementary Table 4. Association of CAT and first four CAT questions with any 
exacerbation during longitudinal follow-up in selected groups of participants 
 CAT 
≥10 points 
Respiratory questions of 
CAT 
≥7 points 
Subgroup (n) AUC 
(95% CI) 
Sensitivity 
/ 
Specificity 
AUC 
(95% CI) 
Sensitivity 
/ 
Specificity 
By gender 
Women (n=437) 0.66 
(0.60, 0.71) 
0.83 / 0.49 0.65 
(0.59, 0.71) 
0.78 / 0.53 
Men (n=394) 0.64 
(0.56, 0.72) 
0.74 / 0.55 0.63 
(0.54, 0.72) 
0.64 / 0.61 
By race 
African Americans 
(n=203) 
0.65 
(0.60, 0.71) 
0.95 / 0.36 0.62 
(0.53, 0.71) 
0.82 / 0.43 
Non-Hispanic Whites 
(n=581) 
0.65 
(0.60, 0.71) 
0.73 / 0.57 0.65 
(0.59, 0.72) 
0.69 / 0.62 
By chronic bronchitis 
No chronic bronchitis 
(n=678) 
0.65 
(0.59, 0.71) 
0.72 / 0.59 0.63 
(0.56, 0.70) 
0.61 / 0.66 
Chronic bronchitis 
(n=153) 
0.56 
(0.52, 0.61) 
0.96 / 0.17 0.56 
(0.52, 0.61) 
0.96 / 0.17 
By smoking status 
Former smokers (n=422) 0.67 
(0.61, 0.74) 
0.75 / 0.60 0.68 
(0.61, 0.75) 
0.71 / 0.66 
Current smokers (n=400) 0.64 
(0.57, 0.70) 
0.84 / 0.43 0.61 
(0.54, 0.68) 
0.74 / 0.48 
By Body mass 
Obese [BMI ≥30] (n=337) 0.60 
(0.54, 0.67) 
0.81 / 0.40 0.60 
(0.53, 0.67) 
0.73 / 0.48 
Normal or overweight 
(n=494) 
0.68 
(0.62, 0.75) 
0.79 / 0.59 0.68 
(0.61, 0.76) 
0.73 / 0.63 
By Asthma status 
Participants with asthma 
(n=161) 
0.59 
(0.53, 0.65) 
0.91 / 0.27 0.60 
(0.53, 0.67) 
0.89 / 0.31 
Participants without 
asthma (n=719) 
0.64 
(0.58, 0.71) 
0.73 / 0.56 0.63 
(0.56, 0.70) 
0.63 / 0.62 
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Supplementary Table 5. Comparison of participants with preserved lung function scoring <7 
versus those scoring ≥7 points on the four respiratory questions of CAT (n=880) 
 CAT score 
<7 points 
(n=477) 
CAT score 
≥7 points 
(n=403) 
p-value 
Demographics 
Age (mean, s.d.) 62.0 (9.7) 59.1 (9.7) <0.001 
Female gender (%) 47.4 56.6 0.007 
African American (%) 18.9 33.5 <0.001 
BMI (mean, s.d.) 28.0 (4.8) 29.8 (5.4) <0.001 
Smoking history 
Pack-years smoked (mean, 
s.d.) 
42.5 (21.7) 45.8 (26.6) 0.04 
Currently smoking (%) 42.4 58.3 <0.001 
Lung function 
FEV1 in liters (mean, s.d.) 2.83 (0.71) 2.61 (0.71) <0.001 
FEV1 % predicted (mean, 
s.d.) 
97.3 (13.9) 92.2 (14.0) <0.001 
Comorbid Conditions (%) 
Obesity (BMI ≥30 kg/m2) 33.1 48.1 <0.001 
Asthma 9.0 29.3 <0.001 
Diabetes  9.6 19.1 <0.001 
Coronary artery disease 4.6 5.7 0.74 
Markers of respiratory impact (%) 
E7 
 
Any respiratory event prior 
to enrollment  
6.7 24.6 <0.001 
Chronic bronchitis symptoms  4.8 35.0 <0.001 
mMRC dyspnea score ≥2 5.9 26.8 <0.001 
Low distance during 6-
minute walking test 
9.9 23.1 <0.001 
Impaired quality-of-life by 
SGRQ total score 
10.9 70.5 <0.001 
Any of the above 27.9 83.6 <0.001 
CAT score 
CAT score (mean, s.d.)  6.0 (4.0) 18.0 (7.0) <0.001 
Additional markers of health impairment  
High burden of anxiety 
symptoms 
17.8 44.9 <0.001 
High burden of depression 
symptoms 
5.5 25.8 <0.001 
Poor sleep quality 49.1 67.5 <0.001 
Fatigue 9.0 41.9 <0.001 
Low exercise tolerance 23.3 60.8 <0.001 
Notes: p-value represents comparison of means or proportions among those identified by each 
strategy. 
Chronic bronchitis was defined as cough and phlegm production for ≥3 consecutive months per 
years for ≥2years. Dyspnea was defined as mMRC score ≥2. Low walking distance as distance 
walked in six minutes <250 m. Impaired quality-of-life as SGRQ total score >25. High burden of 
anxiety symptoms was defined as Hospital Anxiety and Depression (HADS) anxiety score ≥8. 
High burden of depression symptoms as HADS depression score ≥8. Poor sleep quality as 
Pittsburgh Sleep Quality Inventory >5. Fatigue defined as Functional Assessment of Chronic 
Illness Therapy-Fatigue scale ≤33. Low exercise was defined as Veterans Specific Activity 
Questionnaire <5 metabolic units. 
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Supplementary Table 6. Standards for Reporting Diagnostic Accuracy Studies (STARD) 
criteria followed in the current manuscript 
Section & Topic Item 
No. 
Item Reported 
Tittle or Abstract 1 Identification as a study of diagnostic 
accuracy using at least one measure of 
accuracy 
Yes 
Abstract 2 Structured summary of study design, 
methods, results, and conclusions 
Yes 
Introduction 3 Scientific and clinical background, 
including the intended use and clinical 
role of the index test 
Yes 
 4 Study objectives and hypotheses Yes 
Methods    
Study design 5 Whether data collection was planned 
before the index test and reference 
standard were performed (prospective 
study) or after (retrospective study) 
Yes 
Participants 6 Eligibility criteria Yes 
 7 On what basis potentially eligible 
participants were identified (such as 
symptoms, results from previous tests, 
inclusion in registry) 
Yes 
 8 Where and when potentially eligible 
participants were identified (setting, 
location and dates) 
Yes 
 9 Whether participants formed a 
consecutive, random or convenience 
series 
Yes 
Test methods 10b  Reference standard, in sufficient Yes 
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detail to allow replication 
 11 Rationale for choosing the reference 
standard (if alternatives exist) 
Yes 
 12a Definition of and rationale for test 
positivity cut-offs or result categories of 
the index test, distinguishing pre-specified 
from exploratory 
Yes 
 13a Whether clinical information and 
reference standard results were available 
to the performers/readers of the index test 
Yes 
Analysis 14 Methods for estimating or comparing 
measures of diagnostic accuracy 
Yes 
 15 How indeterminate index test or reference 
standard results were handled 
Yes 
 16 How missing data on the index test and 
reference standard were handled 
Yes 
 17 Any analyses of variability in diagnostic 
accuracy, distinguishing pre-specified 
from exploratory 
Yes 
 18 Intended sample size and how it was 
determined 
Yes 
Results   Yes 
Participants 19 Flow of participants, using a diagram Yes 
 20 Baseline demographic and clinical 
characteristics of participants 
Yes 
 21a Distribution of severity of disease in those 
with the target condition 
Yes 
 22 Time interval and any clinical 
interventions between index test and 
reference standard 
Yes 
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Test results 23 Cross tabulation of the index test results 
(or their distribution) by the results of the 
reference standard 
Yes 
 24 Estimates of diagnostic accuracy and their 
precision (such as 95% confidence 
intervals) 
Yes 
 25 Any adverse events from performing the 
index test or the reference standard 
No 
Discussion 26 Study limitations, including sources of 
potential bias, statistical uncertainty, and 
generalizability 
Yes 
 27 Implications for practice, including the 
intended use and clinical role of the index 
test 
Yes 
Other 
information 
28 Registration number and name of registry Yes 
 29 Where the full study protocol can be 
accessed 
Yes 
 30 Sources of funding and other support; role 
of funders 
Yes 
Notes: For answers with Yes, we will provide the page number after there is a pdf version 
available. 
Based on Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential 
items for reporting diagnostic accuracy studies. BMJ 2015;351:h5527. 
 
 SPIROMICS 
Participants enrolled at time 
of analysis: 
2,737 
 
 
Exclude participants who 
are never smokers: 
199 
 
 
 2,538 
 
Exclude participants with 
FEV1/FVC < 0.7: 
1,589 
              
 949  
   
Exclude participants with 
FVC < lower limit normal: 
5 
              
 944  
   
Exclude participants 
without CAT scores: 
64 
              
 Included in cross-sectional 
analyses: 
880 
 
   
Participants without 1-year 
follow-up: 
49 
              
 Included in longitudinal 
analyses: 
831 
 
 
Figure 1. Flow of SPIROMICS participants included in the current analysis 
